Founder & CTIO
Turing Biosciences LLC
Groton, Massachusetts
Eric Luellen is the Founder, CEO & Chief Technology and Innovation Officer of Turing Biosciences, a next-generation biotech company that has solved the combinatorial complexity problem in systems biology. Over the past 30 months, Turing’s Nexus platform has uncovered 59 assets—29 drug candidates and 30 non-invasive diagnostics—across five disease areas, leading to 16 FDA submissions, two Rare Pediatric Disease Designations, and two assets now advancing toward INDs.
Eric leads cross-disciplinary teams working at the intersection of machine learning, immunometabolism, and translational omics. Under his leadership, Nexus has become a new standard for reconstructing causal disease mechanisms directly from human clinical data—analogous in scope to DeepMind’s AlphaFold, but for therapeutic discovery.
Prior to Turing, Eric held senior executive roles in venture-backed biotech firms and global companies, with responsibilities spanning SaMD, indication expansion, regulated diagnostics, strategic partnerships, and AI infrastructure. He is a three-time founder, a published author in systems biology and drug development, and a frequent speaker at scientific and partnering conferences.
Eric holds graduate degrees from Northwestern and UMass Amherst, completed 37 credits in biomedical science at Harvard, and holds multiple advanced certifications. He is an Eagle Scout and the proud father of three.
Disclosure information not submitted.
Evolving Role of AI/ML in Drug Development
Tuesday, May 6, 2025
3:00 PM - 3:10 PM ET
Future Directions: Harmonizing Innovation with Regulation – Panel Discussion
Tuesday, May 6, 2025
3:30 PM - 4:00 PM ET